Role of IL-2 in cancer immunotherapy

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

(2015) Keishi Adachi et al.   CANCER SCIENCE

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

(2015) Dalil Hannani et al.   CELL RESEARCH

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overcoming Resistance to Targeted Therapies in Cancer

(2015) Keara L. Redmond et al.   SEMINARS IN ONCOLOGY

The IL-2 cytokine family in cancer immunotherapy

(2014) Geok Choo Sim et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

(2014) Denise Skrombolas et al.   Expert Review of Clinical Immunology

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

(2014) Elaine T. Lam et al.   JOURNAL OF IMMUNOTHERAPY

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

(2014) Melissa Bersanelli et al.   Cancers

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

(2013) Geok Choo Sim et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?

(2013) Julie R. Brahmer   SEMINARS IN ONCOLOGY

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

(2012) X. Yao et al.   BLOOD

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Regulatory T cells and Foxp3

(2011) Alexander Y. Rudensky   IMMUNOLOGICAL REVIEWS

Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases

(2011) John Puskas et al.   IMMUNOLOGY

Endothelial Nitric Oxide Synthase Is a Key Mediator of Interleukin-2-Induced Hypotension and Vascular Leak Syndrome

(2011) Wolfram E. Samlowski et al.   JOURNAL OF IMMUNOTHERAPY

Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders

(2011) N. Yamamoto et al.   MOLECULAR PHARMACOLOGY

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th17 and Regulatory T Cells in Mediating and Restraining Inflammation

(2010) Dan R. Littman et al.   CELL

Increase of Circulating CD4+CD25highFoxp3+ Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2

(2010) Annika Berntsen et al.   JOURNAL OF IMMUNOTHERAPY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-1β and IL-2 convert human Treg into TH17 cells

(2009) Florence Deknuydt et al.   CLINICAL IMMUNOLOGY

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro

(2009) Yufeng Li et al.   JOURNAL OF IMMUNOLOGY

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

(2008) C. Schliemann et al.   BLOOD

The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer

(2008) K. Wagner et al.   CLINICAL CANCER RESEARCH

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

(2008) F. O. Smith et al.   CLINICAL CANCER RESEARCH

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

(2008) Michael B. Atkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology

Structural Biology of Shared Cytokine Receptors

(2007) Xinquan Wang et al.   Annual Review of Immunology